Keytruda 100 MG/4 ML vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQWF3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $58,506
Award facts
- Contract value 100% obligated
- $58,505.86 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order valued at $58,505.86 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda (pembrolizumab) 100 mg/4 mL vials. The delivery order, awarded on December 5, 2025, with an ultimate completion date of December 29, 2025, was issued without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical supply chain operations for Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal military medical system through its role as a regional prime vendor contractor under the PPV-G GEN V program. The parent indefinite delivery contract, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. The company's extensive product portfolio encompasses oncology treatments, immunosuppressants, biologics, vaccines, and specialty pharmaceuticals, positioning it to fulfill the diverse pharmaceutical requirements of military healthcare operations. This delivery order for Keytruda, an oncology therapeutic, exemplifies the contractor's capability to supply specialized pharmaceutical products supporting Department of Defense patient care needs.
Quick answers
Who was awarded contract SPE2DR26FQWF3?
SPE2DR26FQWF3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 5, 2025.
How much is contract SPE2DR26FQWF3 worth?
The government has obligated $58,506 on SPE2DR26FQWF3.
Is contract SPE2DR26FQWF3 an order under another contract?
Yes. SPE2DR26FQWF3 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWF3 competed?
The extent of competition for SPE2DR26FQWF3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award